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Abstract
Capecitabine, a prodrug of fluorouracil, is a component of many chemotherapy regimens used
to treat a wide variety of malignancies. One of the most common adverse reactions experienced
by those who have been exposed to capecitabine is palmar-plantar erythrodysesthesia (PPE).
PPE is a cutaneous manifestation of chemotherapy-related drug toxicity that has signs and
symptoms of erythema, edema, pain, ulceration, or desquamation of the palms of the hands
and soles of the feet. The signs and symptoms occur with varying severity. There are few
reports of the genitalia being similarly affected. The following case describes a patient with
locally advanced rectal cancer who experienced erythrodysesthesia secondary to a
capecitabine-containing neoadjuvant chemoradiation regimen that primarily and most
significantly involved the genitalia. 
Categories: Dermatology, Radiation Oncology, Oncology
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Introduction
Palmar-plantar erythrodysesthesia (PPE), also known as hand-foot syndrome, acral erythema,
or Burgdorf’s reaction, is a cutaneous side effect associated with some cytotoxic agents used to
treat many of the most common malignancies. Some of the available literature makes a
distinction between PPE and hand-foot syndrome, with some using the terms interchangeably.
For the purposes of this paper, the two terms will be considered to be synonymous. The
syndrome is associated with prolonged administration of the systemic agent and appears to be
dose-dependent. The onset and severity of the disease can be affected by peak plasma
concentrations, total cumulative dose, and administration schedule. It was first described in
1984 when an association with protracted infusion of 5-fluorouracil (5-FU) was noted, but
there was no association with bolus 5-FU [1].
Although the present case involves a capecitabine-containing regimen, there are reported
associations of PPE with all of the following: doxorubicin (particularly pegylated liposomal
doxorubicin), cytarabine (particularly in combination with an anthracycline for treatment of
acute leukemia), docetaxel, 5-FU, bleomycin, cisplatin, cyclophosphamide, daunorubicin,
doxifluridine, etoposide, fludarabine, gemcitabine, hydroxyurea, idarubicin, ixabepilone,
methotrexate, mitotane, paclitaxel, tegafur, thiotepa, vinorelbine. 
Possibly more significant than the agent itself is the drug formulation and administration
1 1 1 2 3
 
Open Access Case
Report  DOI: 10.7759/cureus.7724
How to cite this article
Dricken J, Pettke E, Griffin J A, et al. (April 18, 2020) Scrotal and Penile Erythrodysesthesia Associated
with Neoadjuvant Capecitabine Chemoradiation. Cureus 12(4): e7724. DOI 10.7759/cureus.7724
schedule. The fact that the pegylated liposomal doxorubicin, liposomal daunorubicin,
infusional 5-FU, and capecitabine have a stronger association with toxicities, of which PPE is
included, than other drug formulations and administration schedules that do not result in such
a sustained and prolonged tissue exposure would support this [2].
Various treatments for PPE have been proposed, all with varying and usually disappointing
success. The most common and most successful intervention leading to the resolution of PPE is
an interruption of therapy [3].
Case Presentation
An 87-year-old man presented with a history of intermittent bleeding per rectum for the last
several months. He underwent a colonoscopy and was diagnosed with a moderately
differentiated rectal adenocarcinoma with intact mismatch repair protein expression based on
biopsy results. Magnetic resonance imaging revealed a T3N0 rectal cancer with extensive
involvement of the sphincters, extending from the anorectal junction to 1 cm from the anal
verge (Figure 1). Computed tomography images found no evidence of metastatic disease and
the carcinoembryonic antigen level was 1.9.
FIGURE 1: Pelvic MRI showing rectal mass
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He was described as youthful and had relatively few comorbidities. He had a history of prostate
cancer, for which he underwent brachytherapy eight years prior. Genetic polymorphism testing
was not done.
The plan for neoadjuvant chemoradiation therapy consisted of capecitabine 825 mg/m2 twice
daily (1500 mg twice daily) Monday through Friday, skipping non-radiation days, for six weeks;
and 5040 cGy of radiation delivered over 28 fractions.
After receiving 11 fractions of radiation therapy, the patient started to experience left groin
pain that resolved without intervention. Three days later, he developed numbness of the hands
and feet without erythema nor skin changes. Four days later, he again complained of scrotal
discomfort. The dose of capecitabine was decreased to 1000 mg every AM and 1500 mg every
PM, skipping non-radiation days, for the remaining weeks to complete a total course of six
weeks. The patient stopped taking capecitabine, and the decision was made to stop radiation as
well. At that point, he had received three weeks of capecitabine, and 14 of 28 fractions (2520
cGy of 5040 cGy) radiation.
One day later, he started to have significant diarrhea and hematuria. Over the next few days, he
became dehydrated due to persistent diarrhea and was admitted to the hospital for treatment of
dehydration and electrolyte derangements. Physical examination revealed severe scrotal and
penile desquamation (Figures 2 and 3). He was seen and evaluated by the wound care team, and
empiric treatment was started with silver sulfadiazine cream and antifungal cream. No skin nor
wound cultures were obtained. The length of stay was nine days. By 30 days after discharge
from the hospital, the pain had completely resolved, erythema nearly resolved, and
desquamation significantly improved. 
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FIGURE 2: Scrotal erythema and desquamation
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FIGURE 3: Inguinal and scrotal erythema
In order to evaluate the possibility of radiation-induced dermatitis, the radiation plan and
delivery data were reviewed. The radiation fields were designed to intentionally avoid and limit
the radiation dose to the patient’s genitalia and inguinal region. The initial plan had
documented verification by a medical dosimetrist and a medical physicist. On the first day of
treatment, a radiation output measurement was performed for each beam to further ensure
that the beams were being delivered safely and accurately. These diode measurements were also
all within 1.5% of the expected value and normal tolerances. Upon further investigation, no
errors in the planning or delivery were identified. The patient's alignment, based on cone-beam
CT data, was reviewed and found to have a close agreement between the expected and the
acquired image sets. Finally, the alignment data for the C-RAD Catalyst™ system, the system
that captures a 3D surface map of the patient, was reviewed and showed accurate alignment. 
On follow up with his colorectal surgeon, the rectal mass was noted to be nodular, mobile, less
bulky, and to involve the anal sphincters on the digital rectal exam. Re-staging MRI showed the
rectal mass was no longer visible and only fibrosis was noted at its previous location. A flexible
sigmoidoscopy demonstrated an ulcerated mass. The mass was biopsied and pathology resulted
as moderately differentiated adenocarcinoma. After extensive multi-disciplinary discussions
and obtaining a second opinion, he elected to forego further chemoradiation, and also decided
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against surgery.
Discussion
PPE is a common side effect of capecitabine with a reported incidence of between 28-58%
[4]. As of the time of this case report, there have been eight reported cases of PPE with the
involvement of the scrotum and genitalia, including this one [5-8]. Despite the fact that PPE is
seen in association with many other drugs used to treat malignancies, it appears as though the
involvement of the genitals has been reported more commonly to the administration of
capecitabine. Erythrodysesthesia may be seen in other areas of the body that experience
increased pressure or temperature, such as the buttocks, under the breasts, in the axillae, and
labial area.
Capecitabine, a prodrug of fluorouracil, is a component of many chemotherapy regimens used
to treat a wide variety of malignancies. It may be found to be more appealing than 5-FU because
it is administered orally. Once swallowed, it is readily absorbed from the gastrointestinal tract.
In the liver, a carboxylesterase hydrolyzes much of the compound to 5’-deoxy-5-fluorocytidine
(5’-DFCR). Cytidine deaminase, an enzyme found in most tissues, including tumors, then
converts the 5’-DFCR to 5’-deoxy-5-fluorouridine (5’-DFUR). Subsequently, the enzyme
thymidine phosphorylase hydrolyzes the 5’-DFUR to the active drug 5-FU.
Fluorouracil is a fluorinated pyrimidine antimetabolite. It inhibits thymidylate synthetase,
which ultimately interferes with DNA, and to a lesser degree, RNA synthesis. Fluorouracil
appears to preferentially affect the G1 and S phases of the cell cycle.
Pathophysiology of PPE
As previously described, the conversion of capecitabine to 5-FU requires a series of enzymatic
reactions. Genetic polymorphisms may play a role in increasing a person’s susceptibility to
exhibiting signs and symptoms of toxicity. Although there are about 25 candidate genes
identified in which variation may affect the efficacy and toxicity of capecitabine therapy, two
specific genes are most commonly mentioned. Polymorphisms involving the genes that encode
thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPD) have been
mentioned as possibly contributing to the development of toxicity with capecitabine therapy.
While genetic tests do exist to detect such polymorphisms, it is not standard of care to conduct
testing prior to initiating fluoropyrimidine therapy.
Of all of the genetic polymorphisms thought to be related to fluoropyrimidine intolerance, the
gene that encodes DPD has been most studied. About 3-5% of Caucasians have a partial DPD
deficiency, and 0.2% have a complete deficiency. All patients who are found to have less than
70% DPD activity are considered to be at risk for the development of severe drug-related
toxicities [10]. In the literature review, no case of PPE with genital involvement mentioned
testing for genetic polymorphisms, except for one. The one patient that was tested was found
to have no mutation [5].
The pathophysiology of PPE is not well understood. Those without a genetic polymorphism still
can experience signs and symptoms of toxicity, specifically PPE. One proposed mechanism is
trauma to the palms and soles from normal daily activities leading to the rupture of small
dermal capillaries. This allows the release of the drug into the surrounding tissues, causing an
inflammatory response. The scrotum and genitalia could possibly be considered to sustain a fair
amount of trauma during daily activities, but not nearly to the extent of the palms of the hands
and soles of the feet [11].
Another mechanism that has been described focuses on the eccrine sweat glands. The palms,
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soles, scalp, and genitals contain the highest concentrations of eccrine sweat glands on the
body. There are two different theories that involve the eccrine sweat glands.
One theory is that noninflammatory metaplasia of cuboidal epithelial cells of the eccrine sweat
ducts occurs as a result of the direct toxic effects of the drug, known as eccrine squamous
syringometaplasia (ESS). ESS appears from two to 39 days after initiation of chemotherapy and
is reported as resolving spontaneously in 7-10 days. It has been suggested that histologic
analysis may assist in differentiating ESS from other possible diagnoses [12]. 
A second theory that involves the eccrine sweat glands describes the accumulation of the drug
on the skin surface, allowing it to penetrate the upper epidermis. Here, it shows cumulative
toxic effects by forming free radicals that damage cellular structures. The same mechanism was
implicated in the cutaneous signs and symptoms associated with pegylated liposomal
doxorubicin therapy, and subsequently successfully targeted in preventing and treating the
condition.
Treatment and prevention of PPE
Various treatments for PPE have been suggested, all with varying degrees of efficacy.
Ultimately, what is required in most cases is either interruption or discontinuation of the
treatment. Out of eight cases of PPE with genito-scrotal involvement reported in the literature,
including this case, seven required discontinuation of chemotherapy.
As with the appearance of any sign or symptom of toxicity, dose reduction may be a reasonable
course of action. Lengthening the intervals of the drug administration schedule alone, or in
addition to dose reduction, may be effective [1, 13].
Prophylactic measures may be taken in an attempt to prevent PPE from occurring. One systemic
medication that has been frequently discussed is celecoxib. Celecoxib is a cyclooxygenase-2
(COX-2) inhibitor. Because some of the theories about the pathophysiology of PPE revolve
around a local inflammatory tissue reaction after extravasation of the drug allowing it to
penetrate the stratum corneum likely mediated by COX-2, it was thought that treatment with
celecoxib may decrease the likelihood of development of PPE. In a meta-analysis, celecoxib was
found to be associated with a statistically significant reduction of moderate to severe PPE. The
authors claim that it is the “most promising” agent for the prevention of PPE. Some of the well-
known potential side effects of celecoxib, however, have led some to not be in support of its use
for this purpose [14].
Pyridoxine (vitamin B6) is an agent that is commonly administered to patients undergoing
chemotherapy, with the intention of preventing PPE. It has been suggested that the use of
pyridoxine to either prevent or treat PPE is based on poor evidence. The use of pyridoxine arose
when similarities between PPE and acrodynia from pyridoxine deficiency was noted in rats.
Two separate studies, one randomized clinical trial, and one meta-analysis both came to the
same conclusion [14, 15]. There is no clinical evidence to support the use of pyridoxine to
prevent or ameliorate PPE.
Topical urea is a cream that is applied to the hands and feet. At low concentrations, it acts to
retain moisture. This occurs because topically, urea promotes the uptake of water by the
stratum corneum by allowing it to have a high water-binding capacity. In a meta-analysis, urea
cream failed to demonstrate an advantage in the prevention of all-grades of PPE (Table 1) [16].




Minimal skin changes or dermatitis (e.g., erythema, edema, or hyperkeratosis) without pain
Grade
2
Skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting ADL
Grade
3
Severe skin changes (e.g., peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting self-care
ADL
TABLE 1: PPE common terminology of adverse events
Adopted from [9].
PPE - palmar-plantar erythrodysesthesia; ADL - activities of daily living
Systemic and topical steroids have been used to prevent and/or treat PPE. Their use has been
poorly studied, especially in regard to capecitabine-associated PPE. Most of the literature
regarding the use of steroids to treat and/or prevent PPE is in relation to pegylated liposomal
doxorubicin. Even then, the literature is quite sparse. A study by Drake et al. used
dexamethasone to treat those who experienced PPE after receiving pegylated liposomal
doxorubicin for various gynecologic malignancies. In that study, nine patients developed PPE.
Six received a dexamethasone taper. All six demonstrated a complete or near-complete
resolution of PPE and required no dose modification. All three who did not receive steroids
required treatment delays and dose reductions [16].
Application of topical antiperspirant has been hypothesized to be a potentially beneficial
measure in preventing PPE given the idea that accumulation of the drug on the surface of the
skin may occur via the eccrine sweat glands. One study suggests that the application of topical
aluminum chlorohydrate is well-tolerated and may reduce the incidence of grade 2 or 3 PPE
(Table 1) [17].
With fairly new technology allowing for the detection and measurement of concentrations of
capecitabine on the surface of the skin, some parallels may be drawn between pegylated
liposomal doxorubicin-associated PPE and capecitabine-associated PPE. Pegylated liposomal
doxorubicin spreads evenly on the skin surface, penetrating into the superficial epidermis.
There it shows cumulative toxic effect by forming free radicals that injure cellular structures.
The topical application of an antioxidant ointment was found to be effective in preventing and
treating PPE [18]. This theory was tested in patients who developed PPE secondary to
capecitabine. Topical Mapisal®, an ointment that contains several antioxidants and has a high
radical protection factor, was studied in comparison to topical 10% urea cream. The urea cream
was found to be superior [19]. The topical application of silymarin, another agent rich in
antioxidants, has been studied and found to potentially be useful in delaying the onset of PPE
[19]. Given that one of the theories regarding the etiology of PPE is the accumulation of the
drug on the skin surface due to sweating, it would be reasonable to attempt to mitigate the
effects by controlling sweating. Regional cooling has been suggested as an intervention to
prevent PPE. One study described placing ice packs around the wrists and ankles of patients
receiving pegylated liposomal doxorubicin therapy for gynecologic malignancies. The authors
indicated that the study demonstrated the intervention was an efficacious prevention strategy
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[20].
Conclusions
PPE is a common adverse reaction to capecitabine, as well as many other drugs used to treat
malignancies. Involvement of the genitals is rare but seems to be associated with increased
severity of the adverse reaction. Although genital involvement has been reported with a few
other drugs, it could potentially occur with the administration of any drug associated with the
development of PPE. The symptoms can be debilitating, so early detection is prudent. This may
mean that patients receiving capecitabine therapy need to be specifically asked about skin
changes or pain in the genitals, or even have regular genital examinations.
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